Ex parte WALDRON - Page 4




              Appeal No. 94-2006                                                                                        
              Application 07/586,317                                                                                    


              antibiotic resistance genes in plant cells.”  The examiner's position is summarized in the                
              last sentence of the paragraph bridging pages 3-4 of the examiner's answer as “undue                      
              experimentation would have been required by one of ordinary skill in the art to evaluate a                
              multitude of non-exemplified terminal or internal deletions to identify and characterize                  
              functional portions of the gene product and the corresponding coding regions of the gene.”                
                     As explained in PPG Indus., Inc. v. Guardian Indus. Corp., 75 F.3d 1558, 1564, 37                  
              USPQ2d 1618, 1623 (Fed. Cir. 1996):                                                                       
                     In unpredictable art areas, this court has refused to find broad generic claims                    
                     enabled by specifications that demonstrate the enablement of only one or a                         
                     few embodiments and do not demonstrate with reasonable specificity how to                          
                     make and use other potential embodiments across the full scope of the                              
                     claim.  See, e.g., In re Goodman, 11 F.3d 1046, 1050-52, 29 USPQ2d                                 
                     2010, 2013-15 (Fed. Cir. 1993); Amgen, Inc. v. Chugai Pharmaceutical Co.,                          
                     927 F.2d 1200, 1212-14, 18 USPQ2d 1016, 1026-28 (Fed. Cir.), cert.                                 
                     denied, 502 U.S. 856 (1991); In re Vaeck, 947 F.2d at 496, 20 USPQ2d at                            
                     1445.  Enablement is lacking in those cases, the court has explained,                              
                     because the undescribed embodiments cannot be made based on the                                    
                     disclosure in the specification, without undue experimentation.  But the                           
                     question of undue experimentation is a matter of degree.  The fact that some                       
                     experimentation is necessary does not preclude enablement; what is                                 
                     required is that the amount of experimentation “must not be unduly                                 
                     extensive.”  Atlas Powder Co., v. E.I. DuPont de Nemours & Co., 750 F.2d                           
                     1569, 1576, 224 USPQ 409, 413 (Fed. Cir. 1984).  The Patent and                                    
                     Trademark Office Board of Appeals summarized the point well when it                                
                     stated:                                                                                            
                            The test is not merely quantitative, since a considerable                                   
                            amount of experimentation is permissible, if it is merely                                   
                            routine, or if the specification in question provides a                                     
                            reasonable amount of guidance with respect to the direction in                              
                            which the experimentation should proceed to enable the                                      

                                                           4                                                            





Page:  Previous  1  2  3  4  5  6  7  8  9  Next 

Last modified: November 3, 2007